FIELD: medicine.
SUBSTANCE: invention refers to medicine, and concerns a method for identification of an agent for treating cancer and inflammatory diseases consisting in determining an ability of the agent to react with OG domain MMP-9 wherein said agent is a putative reductive regulator of collagenolytic activity MMP and determining an ability of said agent for reductive regulation of collagenolytic activity MMP-9.
EFFECT: invention provides reduction of collagenolytic activity MMP-9.
10 cl, 7 ex, 7 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ISOLATED ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT SPECIFIC FOR HUMAN IMMUNOGLOBULIN E (VERSIONS), NUCLEIC ACID MOLECULE CODING IT, HOST CELL, METHOD FOR PREPARING ANTIBODY OR ITS ANTIGEN-BINDONG FRAGMENT, PHARMACEUTICAL COMPOSITION, USE THEREOF FOR TREATING IgE-ASSOCIATED DISEASES | 2008 |
|
RU2466140C2 |
| BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
| BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2824959C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| IL-6 BINDING MOLECULES | 2013 |
|
RU2676078C2 |
| ANTI-panNrp ANTIBODY (VERSIONS) | 2007 |
|
RU2454427C2 |
| METHOD FOR GM-CSFRα INHIBITION IN PATIENT | 2012 |
|
RU2639546C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
